Skip to main content
GutCited

Saccharomyces boulardii pour Antibiotic-Associated Diarrhea (AAD)

A

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

En conclusion

Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.

Key Study Findings

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None vs: None Outcome: None Effet: None None

Population: Pediatric population

Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None vs: None Outcome: None Effet: None None

Population: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI Effet: None None

Population: Pediatric patients with GI disorders

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs Effet: L. rhamnosus GG used by 91.8% None

Population: Italian primary care pediatricians

Randomized Controlled Trial n=564 20 weeks Double-blind
High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent …
Dose: None vs: Placebo Outcome: Quality of life Effet: None P < .001

Population: None

Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None vs: None Outcome: C. difficile infection treatment outcomes Effet: None None

Population: Patients with C. difficile infection

Key Statistics

25

Études

5000

Participants

Positive

A

Note

Referenced Papers

Advances in experimental … 2024 2 citations
Advances in experimental … 2019 17 citations
The American journal … 2018 46 citations
Journal of pediatric … 2016 233 citations
Digestive diseases (Basel, … 2016 37 citations
The Cochrane database … 2015 233 citations
Journal of clinical … 2015 35 citations
Journal of clinical … 2011 432 citations
Journal for specialists … 2010 22 citations
American journal of … 2010
European journal of … 2009 91 citations
Current opinion in … 2009 82 citations
Advances in biochemical … 2008 535 citations
American family physician 2008
The Journal of … 2007 265 citations
The American journal … 2001 648 citations
International journal of … 2000 181 citations
Clinical infectious diseases … 1998 346 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

Limite supérieure : Well-tolerated up to 1,000 mg/day in clinical trials

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Mixed 279
None 20 weeks Positive 564
None -- Positive --
None 1 weeks Positive 47
Various probiotic interventions -- Positive --

Moment optimal de prise : Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Effets indésirables signalés

  • Mild gas and bloating
  • Rare: fungemia in critically ill patients with central venous catheters
  • Thirst (yeast may increase water requirements)
  • Very rare: potential environmental contamination risk in ICU settings

Interactions connues

  • Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Apport maximal tolérable : Well-tolerated up to 1,000 mg/day in clinical trials

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

Related Evidence

Autres ingrédients pour Antibiotic-Associated Diarrhea (AAD)

Saccharomyces boulardii pour d'autres pathologies

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.